306 results about "Spike Protein" patented technology

The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).

The invention provides an mVSV virus vector, i.e., attenuated mVSV obtained after multiple modification mutations occur to an M protein amino acid site of a wild Indiana strain VSV, and an optimized heterologous antigen gene is preferentially integrated to a double cloning site area of an mVSV packaging core plasmid pmVSV-Core at the same time. The mVSV virus vector vaccine comprises a heterologous antigen gene which fuses or embeds a target virus between G and L genes of an mVSV vector envelope, wherein the antigen gene comprises an enveloped and embedded antigen gene encoding the target virus, an embedded combination antigen gene or a fused antigen gene; the mVSV virus vector is embedded or fused with a dominant antigen of spike protein S of an SARS-CoV-2 pathogen; the dominant antigen is preferably selected from a receptor binding domain of spike protein S, namely RBD; and a COVID-19 vaccine based on mVSV mediation is formed. The vaccine has good prevention or treatment effect on COVID-19 infected people.

Monoclonal antibody reagents that recognize the SARS-coronavirus (SARS-HCoV) are needed urgently. In this report we describe the development and immunochemical characterisation of mAbs against the SARS-HCoV based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating antigen, resulted in the selection of seventeen mAbs. Five mAbs exhibited Western immunoblot reactivity with the denatured spike protein, of which two demonstrated the ability to neutralize SARS-HCoV in vitro. Another four Western immunoblot-negative mAbs also neutralize the virus. These antibodies will be useful for the development of diagnostic tests, pathogenicity and vaccine studies.

The invention relates to the technical field of medical biology, and specifically discloses a novel coronavirus (SARS-COV-2) spike protein binding molecule and applications thereof. The binding molecule can specifically bind the spike protein of SARS-COV-2 and includes at least one immunoglobulin single variable structural domain. The provided binding molecule can specifically bind the SARS-COV-2-Spike protein and effectively block the binding of the SARS-COV-2-Spike protein and human cell ACE2 receptors, so that the infection process of the SARS-COV-2 on cells can be further blocked, and theinfection and amplification of the SARS-COV-2 can be inhibited.

The present disclosure provides vaccines and compositions based on S antigen proteins of SARS-CoV-2, and specifically relates to recombinant SARS-CoV-2 spike proteins (S proteins) or antigenic fragments thereof, and mRNAs encoding the same. The present disclosure also relates to mRNA comprising a sequence selected from any one of SEQ ID NO. 44 to 47. The present disclosure further relates to mRNA-vector particles, such as lipid nanoparticles (LNPs), comprising the aforementioned mRNAs and compositions, such as vaccine compositions.

The present invention provides an isolated antibody capable of binding to the receptor-binding domain of the spike protein of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) so as to competitively inhibit the binding of the SARS-CoV to host cells. These mAbs or substances can be used: 1) as passive-immunizing agents for prevention of SARS-CoV infection; 2) as biological reagents for diagnosis of SARS-CoV infection; 3) as immunotherapeutics for early treatment of SARS-CoV infection; and 4) as probes for studying the immunogenicity, antigenicity, structure, and function of the SARS-CoV S protein.

This invention provides a vaccine comprising an effective amount of an isolated polypeptide or recombinant protein containing the sequence of the receptor-binding domain in the SARS associated coronavirus spike protein or a functional fragment thereof, or a nucleic acid molecule comprising the sequence of a fragment which encodes the sequence of the receptor-binding domain in the Severe Acute Respiratory Syndrome associated coronavirus spike protein or a functional fragment thereof. This invention provides a composition for increasing the immunogenicity of an antigen comprising an effective amount of an antigen and an IgG Fc domain, its functional fragment, or a substance containing an IgG Fc domain or its functional fragment. The antigen and the IgG Fc may be linked or unlinked. Finally, this invention also provides method for using any of the above compositions for immunization.

The present invention relates to a cell-based method for producing influenza virus vaccines by enriching the population of surface-bound α2,6-sialic acid receptors on a cell surface, such as on a Chinese Hamster Ovary (CHO) cell surface. The host cell therefore presents numerous binding sites to which an influenza virus can bind via its hemagglutinin spike protein and infect the host cell. In contrast to wild-type CHO cells, the surface of the mutated CHO cells of the present invention contains an enriched population of α2,6-sialic acid receptors which makes the inventive CHO cells highly susceptible to viral infection, and therefore safe, effective, and highly efficient cells for rapidly producing influenza vaccines.

The present invention encompasses porcine epidemic diarrhea virus (PEDV) vaccines or compositions. The vaccine or composition may be a vaccine or composition containing PEDV antigens. The invention also encompasses recombinant vectors encoding and expressing PEDV antigens, epitopes or immunogens which can be used to protect porcine animals against PEDV.

A pseudo-virus packaging system of coronaviruses comprises a vesicular stomatitis virus (VSV) vector with a Fluc and EGFP double reporter gene replacing a GP gene and an assembly cell expressing coronavirus spike protein S. The double reporter gene is selected from luciferase and fluorescent protein, and the luciferase reporter gene is preferably a Fluc gene. The fluorescent protein reporter geneis preferably an EGFP gene, and the assembly cell is preferably 293T. The invention further relates to a one-step packaging method of the packaging system; a pseudo-virus with single-cycle infection,low background value and high titer can be quickly packaged through simple, convenient and rapid operation, and the packaging system has the characteristic of being rapid in detection compared with aslow virus mediated pseudo-virus system; the one-step packaging method can be used for researching COVID-19, SARS, MERS and other coronaviruses and other viruses, provides a powerful screening tool for evaluation of antiviral preparations and vaccine, and has wide application value.

The invention discloses a novel coronavirus SARS-CoV-2 S protein detection method. SARS-CoV-2 virus depends on spike protein on the surface to be combined with angiotensin converting enzyme 2 on the surface of a cell so as to enter the cell; according to the method, raw materials commonly used in chemiluminescence immunoassay and ACE2 are easy to purchase from the market, the biotin labeling and the alkaline phosphatase labeling are rapid, the reagent for SARS-CoV-2 S protein detection can be rapidly prepared, and the positive coincidence rate, the negative coincidence rate and the total coincidence rate are high compared with the SARS-CoV-2 fluorescence quantitative PCR result.

The present invention discloses a new coronavirus vaccine based on chimpanzee adenovirus type 68 and MERS-CoV full length membrane protein. The recombinant adenovirus is obtained by transfecting an adenovirus packaging cell with a recombinant plasmid and then performing cell culture; the recombinant plasmid is obtained by inserting a specific DNA molecule into a delta-E1 region of a chimpanzee adenovirus vector AdC68; the specific DNA molecule has a full-length MERS-CoV Spike protein encoding gene; and the adenovirus packaging cell has an adenovirus E1 gene. The present invention also protectsthe recombinant adenovirus expressing the full-length MERS-CoV Spike protein; and a starting strain of the recombinant adenovirus is chimpanzee adenovirus type 68 or non-replicating chimpanzee adenovirus type 68. The developed vaccine against the new coronavirus MERS-CoV has important theoretical guidance value and broad application prospects, and provides a possibility for radical cure of MiddleEast respiratory syndrome.

The invention discloses an optimized SARS coronary virus spike protein gene, which codes the SARS coronary virus S protein or immunogenicity fragment, and has 77+/-3% homology with SARS coronary virus S protein coding sequence(such as SEQ ID NO: 1). The invention also provides vector, host cell and vaccine composition containing a optimized S protein coding sequence, whose expression efficiency is higher in mammal cell, So can stimulate the immune response in mammal to SARS.

The invention provides a stable polypeptide targeting SARS-CoV-2 spike protein. A template amino acid sequence structure of the stable polypeptide is X-(Linker)-CONH-IEEQAKTFLDKFNHEAEDLFYQS-CONH2. Theinvention also provides application of the polypeptide in preparation of a medicine for treating SARS-CoV-2. The invention also provides application of the polypeptide in preparation of a medicine for preventing the SARS-CoV-2 from entering human cells. The polypeptide molecule is combined with the spike protein to block virus from entering the human body by being combined with human ACE2. Experiments of fluorescence polarization detection and the like prove that the polypeptide disclosed by the invention can be well combined with an RBD of the spike protein and has an effect of blocking a virus infection process.

The invention relates to the technical field of biological medicine, in particular to nucleic acid for encoding SARSCoV2 virus spike protein and application of the nucleic acid. Through codon optimization, the invention provides the Spike high-expression novel coronavirus mRNA vaccine based on the TC83Venezuelan Equine Encephalosis Virus (VEEV) in the alpha virus family, and the vaccine can detecta spike antibody after 14 days of inoculation in an animal experiment.

Embodiments of the disclosure concern immunogenic compositions and methods for treating or preventing Severe acute respiratory syndrome (SARS). The compositions and methods concern a portion of the receptor-binding domain (RBD) of the SARS-CoV spike protein. In at least particular cases, a mutated version of a portion of the RBD is utilized, such as a deglycosylated mutant of the RBD.

The invention relates to the technical field of biology, and provides a novel coronavirus COVID-19 antigen fluorescence detection kit and a preparation method thereof. The kit comprises a bottom plate. A sample pad, a combination pad, a coating film and absorbent paper are laid on the bottom plate. The combination pad contains a fluorescent microsphere labeled novel coronavirus COVID-19 Spike protein monoclonal antibody and a fluorescent microsphere labeled goat anti-chicken antibody. The coating film comprises a detection area coating T and a quality control area coating C. The detection areais coated with a novel coronavirus COVID-19 Spike protein monoclonal antibody of which the epitope is different from that of the novel coronavirus COVID-19 Spike protein monoclonal antibody on the combination pad. The quality control area is coated with a chicken IgY antibody. The kit disclosed by the invention can accurately detect whether the novel coronavirus Spike protein exists in a sample or not, so that on-site rapid detection is realized.

Provided are polypeptides derived from the coronaviruses (CoVs) Spike protein (S) characterized by high affinity and specificity the S receptor and its neutralizing antibodies. Further provided are compositions and vaccines, and vaccine-based therapies targeting CoVs, and SARS and MERS viruses in particular.

The invention belongs to the field of biomedicine, and particularly relates to application of a natural sulfated polysaccharide derived from marine organisms as a drug for resisting coronavirus and induced diseases, and application of natural sulfated polysaccharide and pharmaceutically acceptable salts derived from marine organisms in the preparation of a drug combined with spike protein, preparation of an inhibitor of main protease (Mpro), or preparation of a papain-like protease (PLpro) inhibitor. The natural sulfated polysaccharide derived from marine organisms has an obvious effect of inhibiting the proliferation of coronaviruses, and can not only inhibit the spike protein (Spike) on the surface of the coronavirus from binding to host cells, but also inhibit the activity of the MPro and (PLpro), thereby effectively blocking the infection of host cells by coronavirus.

Fusion protein RBD-hFc/RBD-His obtained by combining a novel coronavirus (SARS-CoV-2) spike protein receptor binding structural domain (RBD) with a human immunoglobulin hFc domain or His tag through a genetic engineering means is convenient to extract and purify, stable and controllable in quality, short in time consumption and capable of being produced on a large scale. A vaccine composition prepared from the fusion protein and an adjuvant can increase the solubility and stability of a vaccine, enhance the immunogenicity of the vaccine and prolong the half-life period of the vaccine in vivo. The fusion protein and the vaccine composition thereof can inhibit replication and transmission of SARS-CoV-2 wild type and/or variant strains or prevent the SARS-CoV-2 wild type and/or variant strains from settling in a host, so that novel coronavirus pneumonia caused by the SARS-CoV-2 wild type and/or variant strains can be effectively prevented and/or treated.

The invention relates to a coding amino acid sequence of an armed chimeric antigen receptor capable of specifically knocking out and targeting the SARS-CoV-2 virus SPIKE protein constructed by SARS-CoV-2 virus RNA polymerase, an immune response cell modified by the amino acid sequence, preparation methods and applications. The recombinant vector of the armed chimeric antigen receptor targeting theSARS-CoV-2 virus SPIKE can be constructed by knocking out the SARS-CoV-2 virus RNA polymerase, and a method using the recombinant vector to modify the immune response cell is also constructed; and the obtained novel functional immune response cell can effectively target and attack various viruses. The preparation method of the immune response cell modified by the armed chimeric antigen receptor targeting the SARS-CoV-2 virus SPIKE is simple in step; and the obtained immune response cell targeting the virus SPIKE and modified by virus replication-dependent RNA polymerase has obvious killing effects on coronavirus.